Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

By afschroeder • August 13, 2025

Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I, Cameron DA, Krop IE, Winer EP, Anderson RA. Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093/jnci/djaf198. Epub ahead of print. PMID: 40796347.

Tags: Hematology/Oncology, Publications

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer:[...]

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]

Rethinking the possibilities of adult ring sideroblastic anaemia

Carlson SG, Koo M, Dommaraju S, Song AH, Chai-Ho W. Rethinking the possibilities of adult ring sideroblastic anaemia. Lancet Haematol. 2026 Oct 6:S2352-3026(26)00133-X. doi: 10.1016/S2352-3026(26)00133-X.[...]